CHF Solutions Submits Patent Application for New Peripheral Venous Access Technology for Ultrafiltration and CRRT Systems
12 March 2021 - 12:00AM
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to
changing the lives of patients suffering from fluid overload, today
announced the submission of a patent application for a system to
dramatically improve and simplify venous access for Aquadex™
ultrafiltration and for multiple continuous renal replacement
(CRRT) therapy modalities. The new system is intended to make CRRT
therapies available to all patients through simple, safe, and
easy-to-use peripheral venous access.
Aquadex SmartFlow currently provides ultrafiltration therapy
through either central or peripheral venous access. The new,
innovative technology announced today goes even further to help a
wide range of healthcare providers to establish and maintain
peripheral access for multiple therapy types.
“Access to innovative care solutions for patients with
cardio-kidney disease is our priority at CHF Solutions,”
said Nestor Jaramillo, Jr., President and CEO of CHF
Solutions. “Ease of use and specifically, the option for peripheral
venous access, removes burdens for clinicians to put patients on
ultrafiltration therapies. We’ll continue to invest in and design
new products to meet this need and in making our Aquadex
ultrafiltration system easy to use, flexible in application, and
predictable in outcomes.”
Fluid overload is a major issue among critically ill children
and adults and contributes to increased length of hospitalizations
and readmissions.1 Ultrafiltration with Aquadex™ is associated
with a higher cumulative fluid loss, 50% reduction in the 30-day
readmissions, higher net fluid loss and greater relative reduction
in body weight when compared to pharmacologic therapy.2
About CHF Solutions CHF
Solutions, Inc. (Nasdaq: CHFS) is a medical device company
dedicated to changing the lives of patients suffering from fluid
overload with its novel ultrafiltration therapy system. The company
is focused on developing, manufacturing and commercializing the
Aquadex SmartFlow system for ultrafiltration therapy. CHF Solutions
is headquartered in Minneapolis, Minn., with a wholly-owned
subsidiary in Ireland. The company has been listed on the Nasdaq
Capital Market since February 2012.
About the Aquadex SmartFlow System The Aquadex
SmartFlow system delivers clinically proven therapy using a simple,
flexible and smart method of removing excess fluid from patients
suffering from hypervolemia (fluid overload). The Aquadex SmartFlow
system is indicated for temporary (up to 8 hours) or extended
(longer than 8 hours in patients who require hospitalization) use
in adult and pediatric patients weighing 20 kg or more whose fluid
overload is unresponsive to medical management, including
diuretics. All treatments must be administered by a health care
provider, within an outpatient or inpatient clinical setting, under
physician prescription, both having received training in
extracorporeal therapies.
Forward-Looking Statements Certain statements
in this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements regarding the
benefits of innovations contained in the patent application.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our ability to execute on our commercial strategy, the possibility
that we may be unable to raise sufficient funds necessary for our
anticipated operations, our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual
property protection, our ability to integrate acquired businesses,
our expectations regarding anticipated synergies with and benefits
from acquired businesses, and other risks and uncertainties
described in our filings with the SEC. Forward-looking statements
speak only as of the date when made. CHF Solutions does not assume
any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
1 Costanzo MR et al. JACC. 2017;69(19):2428-45.
2 Grodin, J et al. European Journal of Heart Failure, 2018;
20(7), 1148-1156.
CONTACTS
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
Matt Bacso, CFA
Gilmartin Group LLC
Matt.bacso@gilmartinir.com
MEDIA:
Jessica Stebing
Health+Commerce
260-336-6202
jstebing@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Aug 2024 to Sep 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Sep 2023 to Sep 2024